Form 4: Aprea Therapeutics CEO Oren Gilad Acquires Shares and Stock Options

Aprea Therapeutics' CEO, Oren Gilad, reports acquisition of common stock and stock options, along with existing holdings.

Summary

• Oren Gilad, the President and CEO of Aprea Therapeutics, reported changes in his beneficial ownership of the company's securities.
• On March 27, 2025, Gilad acquired 6,725 shares of common stock and 26,900 stock options.
• The common stock was acquired at $0.00, representing restricted stock units vesting in equal annual installments starting March 27, 2026.
• The stock options have an exercise price of $2.20, with 25% vesting on March 27, 2026, and the remainder vesting ratably over the following 36 months.
• Following these transactions, Gilad directly owns 340,120 shares of common stock and 26,900 stock options.
• He also indirectly owns 1,200 shares through his daughter and 600 shares through his son, but disclaims beneficial ownership of these shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO is increasing their stake in the company, which can be seen as a vote of confidence. However, it's a routine filing related to compensation.

Positives

• The CEO's acquisition of shares and options could be seen as a positive signal, indicating confidence in the company's future performance.
• The vesting schedules for the restricted stock units and stock options incentivize long-term commitment from the CEO.

Future Outlook

The CEO's future ownership will increase as the restricted stock units and stock options vest over the coming years, contingent on continued employment.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by his daughter and son, stating that the report should not be deemed an admission of beneficial ownership for Section 16 purposes.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Vesting schedules for stock options and restricted stock units are common compensation practices in the biotechnology industry, aligning executive incentives with long-term shareholder value.
• Companies like Amgen and Gilead Sciences also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive sign.
• Employees may be motivated by the CEO's commitment to the company's long-term success.

Next Steps

• The restricted stock units will vest annually starting March 27, 2026.
• 25% of the options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months.

Key Dates

Keywords

Aprea Therapeutics, Oren Gilad, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Securities, CEO